News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform [Yahoo! Finance]

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program [Yahoo! Finance]

Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Kornberg Roger D.

Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Borisenko Grigory G.

Form 4 Xenetic Biosciences, For: Dec 11 Filed by: VINOGRADOV ALEXEY ANDREEVICH

Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Dastoor Firdaus J.

Form 8-K Xenetic Biosciences, For: Dec 11

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}